The Zhitong Finance App learned that Goldman Sachs released a research report stating that due to Kangzhe Pharmaceutical's performance and sales growth prospects becoming more conservative in a challenging environment, it lowered its profit forecast by 3.3%, 4.2% and 9.4% for each year from 2026 to 28, and the target price was lowered from HK$19.5 to HK$17.96, maintaining a “buy” rating. The company's revenue in the first half of the year was 4.5 billion yuan, up 12.5% year-on-year, below the bank's expectations of 18% growth. The three core VBP products performed better than expected. Despite the slowdown in revenue growth, net profit rose 5% year over year to 986 million yuan, which is roughly in line with the forecast. Mainly due to lower sales expenses than expected, it remained flat year-on-year and fell from 35.6% to 32% of sales.

The Zhitong Finance App learned that Goldman Sachs released a research report stating that due to Kangzhe Pharmaceutical's performance and sales growth prospects becoming more conservative in a challenging environment, it lowered its profit forecast by 3.3%, 4.2% and 9.4% for each year from 2026 to 28, and the target price was lowered from HK$19.5 to HK$17.96, maintaining a “buy” rating. The company's revenue in the first half of the year was 4.5 billion yuan, up 12.5% year-on-year, below the bank's expectations of 18% growth. The three core VBP products performed better than expected. Despite the slowdown in revenue growth, net profit rose 5% year over year to 986 million yuan, which is roughly in line with the forecast. Mainly due to lower sales expenses than expected, it remained flat year-on-year and fell from 35.6% to 32% of sales.